Further molecular analysis revealed that the overexpressed HDAC2 and HDAC5 promote the development of hormone therapy resistance in ER+ breast cancer cells through multiple mechanisms including up-regulation of the pro-survival mTOR-survivin signaling pathway, and down-regulation of the tumor suppressing molecules, p53 and miR-125a-5p. Here, HDAC5 is linked to breast cancer.